Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 14/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28470333 | 0.81 | LMNA (0.74) | LMNAMAPTMEN1GAAKMT2A | |
| SCHEMBL9401163 | 0.79 | LMNA (0.70) | LMNAMAPTMEN1GAAKMT2A | |
| SCHEMBL17520528 | 0.79 | LMNA (0.73) | LMNAMAPTMEN1GAAKMT2A | |
| SCHEMBL8372051 | 0.78 | LMNA (0.69) | LMNAMAPTMEN1GAAKMT2A | |
| SCHEMBL11112953 | 0.78 | MEN1 (0.64) | LMNAMAPTMEN1GAAKMT2A | |
| SCHEMBL9928821 | 0.78 | PDE5A (0.63) | ABCG2ABCB1 | |
| SCHEMBL9928823 | 0.78 | PDE5A (0.63) | ABCG2ABCB1 | |
| SCHEMBL29630338 | 0.75 | LMNA (0.61) | LMNAABCG2ABCB1ALDH1A1BCHE | |
| SCHEMBL30196515 | 0.74 | BCHE (0.78) | LMNAMAPTMEN1GAAKMT2A | |
| SCHEMBL17520529 | 0.73 | LMNA (0.62) | LMNAMAPTMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | LMNA 3422/4885MAPT 4328/4885MEN1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.